Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
revimmune logo — Comprehensive T-cell support and advanced immune therapies f...

revimmune

Comprehensive T-cell support and advanced immune therapies for treating complex immune disorders.

5 employees Manufacturing

General Information

Company Name revimmune
Employees 5
Industries Manufacturing
Social

Get notified when revimmune moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About revimmune

RevImmune Inc. is a company that focuses on T-Cell Technology & Development, offering comprehensive T-cell support and advanced immune therapies for treating complex immune disorders. Their flagship product, IL-7, plays a crucial role in T cell development, expansion, proliferation, and mobilization. The company is engaged in the research and development of medicines for immune modulation, particularly targeting lymphopenia-driven diseases. RevImmune's core technology, IL-7, holds promise for the treatment of various conditions, and the company is currently working on CYT107 immune therapy for infectious diseases and cancer. They operate in the manufacturing industry. Although specific details such as the founding date, headquarters, last investment and investors are not provided, RevImmune's focus on cutting-edge T-cell support and immune therapies positions them as a promising player in the rapidly evolving field of immunotherapy. With a clear focus on addressing unmet medical needs, RevImmune's innovative approach has the potential to make a significant impact in the treatment of immune disorders.

Taxonomy: T-cell therapy, immunotherapy, immune disorders, IL-7, T-cell development, immune modulation, lymphopenia, CYT107, immune therapy, infectious diseases, cancer treatment

No funding data available for revimmune yet.

Get notified when revimmune raises funding

revimmune Alternatives & Competitors

revimmune vs
NKGen Biotech, Inc.
NKGen Biotech, Inc. United States

Maximizing immune integrity through the development of unique natural killer (NK) cell therapies.

54 employees
revimmune vs
Repertoire Immune Medicines
Repertoire Immune Medicines United States

Repertoire is a biotechnology company creating a new category of immune medicines for cancer and aut...

Series B
86 employees
Biotechnology, Health and Wellness
revimmune vs
Immunis, Inc.
Immunis, Inc. United States

Promoting healthspan with novel, stem cell-derived biologics for age-related diseases and immune dys...

Series Unknown
18 employees
Biotechnology

FAQ About revimmune

Comprehensive T-cell support and advanced immune therapies for treating complex immune disorders.
revimmune operates in the following industries: Manufacturing.
revimmune has approximately 5 employees.
Top alternatives and competitors to revimmune include NKGen Biotech, Inc., Repertoire Immune Medicines, Immunis, Inc., Tizona Therapeutics, Inc., Cogen Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
revimmune and NKGen Biotech, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors revimmune and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy